“…Globally, the greatest burden and highest incidence of IMD is in infants and young children, with a second peak in adolescents, 1 , 4 , 5 while more recent epidemiological trends indicate an increased burden in adults and the elderly, where case fatality rates (CFRs) are also higher. 1 , 7 , 13 , 14 Global epidemiology shows substantial geographical variation, both in terms of disease burden and in the relative importance of specific serogroups in local or regional IMD epidemiology, 1 , 4 , 5 with temporal shifts driven by both cyclic epidemiologic patterns, disease outbreaks, 15 and the introduction of effective vaccines against major pathogenic serogroups. Use of conjugated monovalent MenC vaccines, quadrivalent MenACWY vaccines and protein-based vaccines against MenB in national immunization programs (NIPs), mostly targeting infants and adolescents, has led to substantial declines in the IMD burden in these at-risk populations, 1 , 5 , 16 , 17 …”